Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo.
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisEtanercept for the treatment of rheumatoid arthritisCytokines sing the blues: inflammation and the pathogenesis of depressionSelf-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studiesComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyTNF inhibitor therapy for rheumatoid arthritisBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelBench to bedside: tumor necrosis factor-alpha: from inflammation to resuscitation.The concept of depression as a dysfunction of the immune systemThe fiery landscape of depression: A review of the inflammatory hypothesis.Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatmentDrugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).InforMatrix: treatment of rheumatoid arthritis using biologicals.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesThe Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database.Update on the use of etanercept across a spectrum of rheumatoid disorders.Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activityB cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.Depression and health-related quality of life in patients with rheumatoid arthritis.Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-AnalysisThe biology of depression in cancer and the relationship between depression and cancer progression.Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept.Have the annual trends of total hip arthroplasty in rheumatoid arthritis patients decreased?Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis.Health-related quality of life in patients with primary Sjögren's syndrome: relationship with serum levels of proinflammatory cytokines.Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 monthsEfficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
P2860
Q24185797-1F0AB8B6-26A9-4775-AD4D-24FD5E390C94Q24202751-798FB0C3-D1A9-4DC2-A129-6548981B66E9Q24633065-60539447-F08A-4C2E-902B-7E9D40355D4FQ24795506-A8BEA832-4DD7-402C-B1ED-E5997416F9CAQ27694496-6F63376A-A689-4581-BFEF-196F897D8CA7Q28972424-CDA8203A-5BC6-4953-89F5-62CE4180BE4DQ30234528-B7220093-AB70-4FBB-9AC6-B044AE75A35BQ30235341-067108E5-820F-494B-8A45-E255683C8D4AQ30957102-ADE6468C-F96B-4530-AD77-BA1151E6FE6DQ33328963-89A3D5B6-7607-485D-82F9-A7D2B82A2F51Q33573112-A3D43FD6-9E35-40D0-A8AC-EA9DB44F7CB7Q33740641-D533E10D-6147-4F2A-8E9E-CF4B6A2A7682Q34013294-9985FC9C-C9CA-4000-B318-3752F952D0E9Q34407371-DC6265AD-9CEC-484F-B7B9-41E44D028D58Q34658493-4B9F8E2E-ECF0-4422-95A6-E978F84D89E7Q35636868-EF2C5395-63F9-43AA-8B63-D75379CCE080Q35637985-E21254FE-63F5-4691-BB6D-4D3B86A457A8Q35638735-E2144C12-7BEE-44F6-96B4-3EE057CF3655Q35780354-E6AD9ADB-7AFB-4A50-B06D-57CEF60BEF5CQ36195284-AE7B57C6-B68D-4E60-B4B4-734A602BE9A3Q36573901-C2C26DDB-EF3B-4129-8424-A4C720A66B0CQ36724093-8A153578-87A2-49EC-8024-2E34CED29288Q37208475-484567A8-DBBA-4257-92F1-E6DEAD52340CQ37290628-A4863F96-44D5-416A-B85F-F3915B51947BQ37347655-682A2594-A94D-4137-AB9A-5ADFE967349BQ37586921-A3A618FF-BC17-4B50-92AC-415288B9EAA4Q37609406-49F3E2C3-3DFF-48BA-AC21-752D3F22CA6AQ37717012-89B541DC-A501-4BA1-AE95-3569108416E2Q38203302-6867B0D1-D1E4-4E5C-A197-004F1A2FB537Q44566796-D0CD578D-D50C-447C-B626-ECCF29C324C6Q47139001-BAF4322F-A277-4E28-88E2-26DC7EF85A14Q47896819-7DDFA0E1-670E-4B75-B740-E54A4298A592Q49146243-EE0F57F1-A850-4AEF-A9F0-2E8161F1806EQ56552256-A29BBAF3-404D-4CCA-9354-C364747F10FAQ58732393-93527E59-0589-49D2-9903-74875BBCB33C
P2860
Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Health-related quality of life ...... receive etanercept or placebo.
@en
type
label
Health-related quality of life ...... receive etanercept or placebo.
@en
prefLabel
Health-related quality of life ...... receive etanercept or placebo.
@en
P2093
P1476
Health-related quality of life ...... receive etanercept or placebo.
@en
P2093
P304
P356
10.1016/S0149-2918(00)87984-9
P577
2000-01-01T00:00:00Z